GAMBARAN PENGOBATAN PASIEN HIPERTENSI DI PUSKESMAS SEYEGAN SLEMAN YOGYAKARTA PERIODE JANUARI-MARET 2018

2018 ◽  
pp. 1-6
Author(s):  
Agustina Susilowati ◽  
Annisa Meylana Wardani
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Beta Blocker ◽  
Ace Inhibitor ◽  
Channel Blocker ◽  
Converting Enzyme

    Hipertensi adalah suatu kondisi dimana terjadi peningkatan tekanan darah lebih bescar dari 90/140 mmHg. Menurut profil kesehatan kabupaten Sleman (2012) penyakit hipertensi menempati peringkat ke dua dari sepuluh besar penyakit rawat jalan. Tujuan dari penelitian ini adalah mengetahui pola peresepan obat hipertensi dan penggunaan obat antihipertensi secara tunggal dan kombinasi obat pada pasien hipertensi di Puskesmas Seyegan Sleman Yogyakarta periode Januari-Maret 2018.    Jenis penelitian ini yaitu deskriptif non eksperimental dengan pengumpulan data rekam medik pasien hipertensi. Data yang diperoleh dianalisis secara deskriptif yaitu menggambarkan dengan persentase, diagram atau tabel.    Hasil penelitian menunjukkan bahwa pola peresepan obat antihipertensi di Puskesmas Seyegan Sleman Yogyakarta adalah golongan diuretik, Calcium Channel Blocker (CCB), Angiotensin Converting Enzyme (ACE) Inhibitor, Angiotensin Reseptor Blocker (ARB), dan Beta Blocker. Penggunaan obat antihipertensi tunggal yang digunakan adalah golongan CCB 66,67%, ACE Inhibitor 6,41%, dan ARB 1,28%. Sedangkan penggunaan obat antihipertensi untuk kombinasi dua jenis 19,24%, kombinasi tiga jenis 6,40%.    Pola peresepan obat antihipertensi yang digunakan di Puskesmas Seyegan Sleman Yogyakarta adalah golongan diuretik, CCB, ACE Inhibitor, ARB, dan Beta Blocker. Penggunaan obat antihipertensi tunggal yang paling banyak digunakan adalah golongan CCB dan untuk obat kombinasi dua jenis adalah golongan CCB dengan ACE Inhibitor.

Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema and Cough

2016 ◽  
Vol 51 (4) ◽  
pp. 293-300 ◽  
Author(s):  
Pär Hallberg ◽  
Julia Nagy ◽  
Malgorzata Karawajczyk ◽  
Leif Nordang ◽  
Gunilla Islander ◽  
...  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Ace Inhibitors ◽  
Ace Inhibitor ◽  
Channel Blocker ◽  
Multiple Model ◽  
Converting Enzyme ◽  
Male Sex ◽  
Time To Onset

Background: Angioedema is a rare and serious adverse drug reaction (ADR) to angiotensin-converting enzyme (ACE) inhibitor treatment. Dry cough is a common side effect of ACE inhibitors and has been identified as a possible risk factor for angioedema. Objective: We compared characteristics between patients with ACE inhibitor–induced angioedema and cough with the aim of identifying risk factors that differ between these adverse events. Methods: Data on patients with angioedema or cough induced by ACE inhibitors were collected from the Swedish database of spontaneously reported ADRs or from collaborating clinicians. Wilcoxon rank sum test, Fisher’s exact test, and odds ratios (ORs) with 95% CIs were used to test for between-group differences. The significance threshold was set to P <0.00128 to correct for multiple comparisons. Results: Clinical characteristics were compared between 168 patients with angioedema and 121 with cough only. Smoking and concomitant selective calcium channel blocker treatment were more frequent among patients with angioedema than cough: OR = 4.3, 95% CI = 2.1-8.9, P = 2.2 × 10-5, and OR = 3.7, 95% CI = 2.0-7.0, P = 1.7 × 10-5. Angioedema cases were seen more often in male patients (OR = 2.2, 95% CI = 1.4-3.6, P = 1.3 × 10-4) and had longer time to onset and higher doses than those with cough ( P = 3.2 × 10-10 and P = 2.6 × 10-4). A multiple model containing the variables smoking, concurrent calcium channel blocker treatment, male sex, and time to onset accounted for 26% of the variance between the groups. Conclusion: Smoking, comedication with selective calcium channel blockers, male sex, and longer treatment time were associated with ACE inhibitor–induced angioedema rather than cough.

scholarly journals Is it an advantage or disadvantage to usage angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in COVID-19 patients?

2020 ◽  
Vol 8 (12) ◽  
pp. 4200
Author(s):  
Feridun Gurlek ◽  
Eyyüp Tasdemir
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Beta Blocker ◽  
Channel Blocker ◽  
Enzyme Inhibitor ◽  
Antihypertensive Drugs ◽  
Severe Pneumonia ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

Background: The use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) is an important problem for clinicians who treat coronavirus disease (COVID-19) in patients with hypertension. The aim of the study was to reduce the confusion in this matter to some extent.Methods: This study was carried out in the Health Sciences University, Bursa High Specialization Training and Research Hospital between 23 March to 23 June 2020. Patients were evaluated using thorax computed tomography (CT) taken during hospitalization with severity and risk scoring, confusion, uraemia, respiratory rate, blood pressure, age ≥65 years, score >2 (CURB-65) for pneumonia.Results: The rate of severe pneumonia was significantly higher in the group using ACEI and ARBs. CURB 65 high risk observation rate was significantly higher in the group with ACEI and ARB using. The rate of severe pneumonia observed was significantly higher in the any antihypertensive drugs using group. This risk height is more pronounced in those using ACEI and ARBs. The mortality rate of our 500 patients with COVID-19 was 2.2% (11/500). There was no history of hypertension in these 4 patients, but 1 (1/4) of these 4 patients had diabetes. Six patients were taking ACEI and/or ARB in combination with their diuretic, calcium channel blocker and beta blocker. Only one patient was taking calcium channel blocker and beta blocker.  Conclusions: The risk of severe pneumonia may increase in COVID-19 positive patients using any antihypertensive drug. It was more pronounced in those using ACEI and ARB. We believe that more comprehensive studies are needed in this about.

Sign in / Sign up

Export Citation Format

Share Document